{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:58:10Z","timestamp":1793249890597,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T00:00:00Z","timestamp":1657324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/igo\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP48979"],"award-info":[{"award-number":["OPP48979"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020171","name":"Foreign, Commonwealth and Development Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008169","name":"Minneapolis Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008169","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R015600\/1"],"award-info":[{"award-number":["MR\/R015600\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.eclinm.2022.101585","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:08:15Z","timestamp":1659485295000},"page":"101585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"special_numbering":"C","title":["Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6985-3541","authenticated-orcid":false,"given":"Lisa","family":"Staadegaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9292-5670","authenticated-orcid":false,"given":"Minttu M.","family":"R\u00f6nn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirali","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan E.","family":"Bellerose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bloem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Brisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8363-4388","authenticated-orcid":false,"given":"Mathieu","family":"Maheu-Giroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruanne V.","family":"Barnabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Drolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Mayaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shona","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Boily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eclinm.2022.101585_bib0001","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1586\/14760584.2016.1110025","article-title":"Human papillomavirus vaccination in HIV-infected women: Need for increased coverage","volume":"15","author":"Kojic","year":"2016","journal-title":"Expert Rev Vaccines"},{"issue":"22","key":"10.1016\/j.eclinm.2022.101585_bib0002","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/jnci\/djs395","article-title":"Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model\u2013based analysis","volume":"104","author":"Van de Velde","year":"2012","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.eclinm.2022.101585_bib0003","unstructured":"Cervical cancer. [cited 2022 Jan 19]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cervical-cancer"},{"key":"10.1016\/j.eclinm.2022.101585_bib0004","unstructured":"RIVM. Projected direct benefit of vaccination against HPV. [cited 2022 Feb 19]. Available from: https:\/\/www.rivm.nl\/documenten\/hpv-vaccination-in-netherlands"},{"key":"10.1016\/j.eclinm.2022.101585_bib0005","unstructured":"PATH. Expanding access to HPV vaccines. [cited 2022 Feb 19]. Available from: https:\/\/www.path.org\/media-center\/expanding-access-hpv-vaccines-path-evaluate-safety-and-immunogenicity-new-hpv-vaccine\/"},{"issue":"3","key":"10.1016\/j.eclinm.2022.101585_bib0006","first-page":"52","article-title":"The nonavalent vaccine: a review of high-risk HPVs and a plea to the CDC","volume":"8","author":"Yusupov","year":"2019","journal-title":"Am J Stem Cells"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101585_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/v13020280","article-title":"Distribution of human papillomavirus (hpv) genotypes in HIV-Negative and HIV-Positive women with cervical intraepithelial lesions in the eastern cape province, South Africa","volume":"13","author":"Taku","year":"2021","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101585_bib0008","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1473-3099(17)30653-9","article-title":"Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis","volume":"18","author":"Lin","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eclinm.2022.101585_bib0009","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jinf.2012.10.024","article-title":"Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer","volume":"66","author":"Chelimo","year":"2013","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101585_bib0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/vaccines8010026","article-title":"Hpv-specific systemic antibody responses and memory b cells are independently maintained up to 6 years and in a vaccine-specific manner following immunization with cervarix and gardasil in adolescent and young adult women in vaccination programs in Italy","volume":"8","author":"Nicoli","year":"2020","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.eclinm.2022.101585_bib0011","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/cid\/cix797","article-title":"A 12-Year Follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 Nordic Countries","volume":"66","author":"Kjaer","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eclinm.2022.101585_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.pvr.2020.100203","article-title":"Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up","volume":"10","author":"Olsson","year":"2020","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.eclinm.2022.101585_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100401","article-title":"Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries","volume":"23","author":"Kjaer","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"10197","key":"10.1016\/j.eclinm.2022.101585_bib0014","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.eclinm.2022.101585_bib0015","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1016\/S2214-109X(16)30099-7","article-title":"Global estimates of human papillomavirus vaccination coverage by region and income level: A pooled analysis","volume":"4","author":"Bruni","year":"2016","journal-title":"Lancet Glob Heal"},{"issue":"14","key":"10.1016\/j.eclinm.2022.101585_bib0016","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV Vaccination and the Risk of Invasive Cervical Cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2022.101585_bib0017","unstructured":"Cervical Cancer Elimination Initiative. [cited 2022 Apr 19]. Available from: https:\/\/www.who.int\/initiatives\/cervical-cancer-elimination-initiative"},{"issue":"3","key":"10.1016\/j.eclinm.2022.101585_bib0018","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eclinm.2022.101585_bib0019","unstructured":"World Health Organisation. Cancer Today. [cited 2022 Mar 19]. Available from: https:\/\/gco.iarc.fr\/today\/home"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101585_bib0020","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","article-title":"Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis","volume":"8","author":"Arbyn","year":"2020","journal-title":"Lancet Glob Heal"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101585_bib0021","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S2214-109X(20)30459-9","article-title":"Estimates of the global burden of cervical cancer associated with HIV","volume":"9","author":"Stelzle","year":"2021","journal-title":"Lancet Glob Heal"},{"key":"10.1016\/j.eclinm.2022.101585_bib0022","unstructured":"UNAIDS. HPV, HIV and cervical cancer: leveraging synergies to save women's lives. [cited 2018 Nov 11]. Available from: http:\/\/www.unaids.org\/en\/resources\/documents\/2016\/HPV-HIV-cervical-cancer"},{"issue":"6","key":"10.1016\/j.eclinm.2022.101585_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25110","article-title":"Evidence of synergistic relationships between HIV and Human Papillomavirus (HPV): systematic reviews and meta-analyses of longitudinal studies of HPV acquisition and clearance by HIV status, and of HIV acquisition by HPV status","volume":"21","author":"Looker","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.eclinm.2022.101585_bib0024","article-title":"HIV-positive women have higher risk of HPV infection, precancerous lesions, and cervical cancer: a systematic review and meta-analysis","volume":"1","author":"Liu","year":"2018","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.eclinm.2022.101585_bib0025","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s11904-014-0224-x","article-title":"HPV and anal cancer in HIV-infected individuals: a review","volume":"11","author":"Schim van der Loeff","year":"2014","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"8","key":"10.1016\/j.eclinm.2022.101585_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-015867","article-title":"Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point - registry-based follow-up of three cohorts from randomized trials","volume":"7","author":"Lehtinen","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.eclinm.2022.101585_bib0027","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2022.101585_bib0028","series-title":"Randomized controlled trials of human papillomavirus vaccines: Systematic reviews prepared by Cochrane Response","year":"2016"},{"issue":"12","key":"10.1016\/j.eclinm.2022.101585_bib0029","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/14760584.2018.1548282","article-title":"Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials","volume":"17","author":"Arbyn","year":"2018","journal-title":"Expert Rev Vaccines"},{"issue":"46","key":"10.1016\/j.eclinm.2022.101585_bib0030","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.1016\/j.vaccine.2018.09.059","article-title":"Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status","volume":"36","author":"Mugo","year":"2018","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.eclinm.2022.101585_bib0031","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/infdis\/jit657","article-title":"Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial","volume":"209","author":"Toft","year":"2014","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.eclinm.2022.101585_bib0032","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1086\/656320","article-title":"Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men","volume":"202","author":"Wilkin","year":"2010","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.eclinm.2022.101585_bib0033","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1177\/0956462419852224","article-title":"Safety and efficacy of human papillomavirus vaccination for people living with HIV: A systematic review and meta-analysis","volume":"30","author":"Zhan","year":"2019","journal-title":"Int J STD AIDS"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101585_bib0034","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/21645515.2019.1656481","article-title":"A systematic review of immunogenicity, clinical efficacy and safety of human papillomavirus vaccines in people living with the human immunodeficiency virus","volume":"16","author":"Mavundza","year":"2020","journal-title":"Hum Vaccines Immunother"},{"issue":"6","key":"10.1016\/j.eclinm.2022.101585_bib0035","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1071\/SH14015","article-title":"Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives","volume":"11","author":"Toft","year":"2014","journal-title":"Sex Health"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101585_bib0036","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1038\/s41598-021-83727-7","article-title":"Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: a systematic review and meta-analysis","volume":"11","author":"Zizza","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.eclinm.2022.101585_bib0037","article-title":"Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males","author":"Bergman","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.eclinm.2022.101585_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.eclinm.2022.101585_bib0039","unstructured":"U.S. National Institute of Health. ClinicalTrials.gov. [cited 2019 Jan 10]. Available from: https:\/\/clinicaltrials.gov\/ct2\/home"},{"key":"10.1016\/j.eclinm.2022.101585_bib0040","unstructured":"World Health Organization. International clinical trials registry platform search portal. 2014 [cited 2019 Oct 10]. Available from: http:\/\/apps.who.int\/trialsearch\/Default.aspx"},{"key":"10.1016\/j.eclinm.2022.101585_bib0041","series-title":"Better systematic review management","year":"2020"},{"issue":"3","key":"10.1016\/j.eclinm.2022.101585_bib0042","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101585_bib0043","first-page":"138","article-title":"The inverse of the freeman-tukey double arcsine transformation","volume":"32","author":"Miller","year":"1978","journal-title":"Am Stat"},{"key":"10.1016\/j.eclinm.2022.101585_bib0044","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"British Medical Journal. BMJ Publishing Group"},{"issue":"3","key":"10.1016\/j.eclinm.2022.101585_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting Meta-Analyses in R with the metafor Package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"10.1016\/j.eclinm.2022.101585_bib0046","unstructured":"ClinicalTrials.gov. Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males. 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01209325"},{"issue":"3","key":"10.1016\/j.eclinm.2022.101585_bib0047","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/QAI.0000000000002258","article-title":"Brief Report: Persistence of Non-Vaccine Oncogenic HPV Genotypes in Quadrivalent HPV-Vaccinated Women Living With HIV","volume":"83","author":"McClymont","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101585_bib0048","doi-asserted-by":"crossref","first-page":"ciu238","DOI":"10.1093\/cid\/ciu238","article-title":"Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-Infected women","volume":"59","author":"Kojic","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eclinm.2022.101585_bib0049","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pvr.2018.08.002","article-title":"Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1","volume":"6","author":"Cespedes","year":"2018","journal-title":"Papillomavirus Res"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101585_bib0050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QAI.0b013e3181de8d26","article-title":"Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old","volume":"55","author":"Levin","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"40","key":"10.1016\/j.eclinm.2022.101585_bib0051","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1016\/j.vaccine.2016.08.016","article-title":"HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine","volume":"34","author":"Money","year":"2016","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.eclinm.2022.101585_bib0052","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/cid\/cit319","article-title":"Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women","volume":"57","author":"Kahn","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101585_bib0053","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/QAI.0000000000001355","article-title":"Brief report: antibody responses to quadrivalent hpv vaccination in HIV-Infected young women as measured by total igg and competitive luminex immunoassay","volume":"75","author":"Kahn","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"13","key":"10.1016\/j.eclinm.2022.101585_bib0054","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.vaccine.2017.02.021","article-title":"Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine","volume":"35","author":"Levin","year":"2017","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.eclinm.2022.101585_bib0055","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/INF.0000000000001874","article-title":"Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in girls living with HIV","volume":"37","author":"Brophy","year":"2018","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101585_bib0056","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/v13020144","article-title":"Effectiveness of the quadrivalent hpv vaccine in preventing anal \u2265 HSILs in a spanish population of HIV+ MSM aged >26 years","volume":"13","author":"Hidalgo-Tenorio","year":"2021","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.eclinm.2022.101585_bib0057","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/cid\/ciy274","article-title":"A randomized, placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 years or older: aids clinical trials group protocol a5298","volume":"67","author":"Wilkin","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.eclinm.2022.101585_bib0058","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/cid\/ciy575","article-title":"The efficacy of the quadrivalent human papillomavirus vaccine in girls and women living with human immunodeficiency virus","volume":"68","author":"McClymont","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101585_bib0059","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/QAI.0000000000002657","article-title":"Safety and immunogenicity of the quadrivalent vaccine in indian women living with HIV","volume":"87","author":"Palefsky","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eclinm.2022.101585_bib0060","unstructured":"ClinicalTrials.gov. Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women. [cited 2021 Jan 3]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00710593"},{"key":"10.1016\/j.eclinm.2022.101585_bib0061","unstructured":"ClinicalTrials.gov. Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women - Full Text View. [cited 2021 Feb 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01461096"},{"issue":"8","key":"10.1016\/j.eclinm.2022.101585_bib0062","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/infdis\/jis489","article-title":"Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children","volume":"206","author":"Weinberg","year":"2012","journal-title":"J Infect Dis"},{"issue":"43","key":"10.1016\/j.eclinm.2022.101585_bib0063","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1016\/j.vaccine.2017.05.069","article-title":"Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations","volume":"35","year":"2017","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.eclinm.2022.101585_bib0064","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/QAD.0000000000001773","article-title":"Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children","volume":"32","author":"Weinberg","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.eclinm.2022.101585_bib0065","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1016\/j.vaccine.2008.09.073","article-title":"HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine","volume":"26","author":"Joura","year":"2008","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101585_bib0066","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3018(17)30149-2","article-title":"Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis","volume":"5","author":"Kelly","year":"2018","journal-title":"Lancet HIV"},{"issue":"10108","key":"10.1016\/j.eclinm.2022.101585_bib0067","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"29","key":"10.1016\/j.eclinm.2022.101585_bib0068","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1016\/j.vaccine.2020.05.004","article-title":"Effectiveness of \u201ccatch-up\u201d human papillomavirus vaccination to prevent cervical neoplasia in immunosuppressed and non-immunosuppressed women","volume":"38","author":"Silverberg","year":"2020","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101585_bib0069","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1016\/S2352-3018(19)30434-5","article-title":"Association of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: a systematic review and meta-analysis","volume":"7","author":"Kelly","year":"2020","journal-title":"lancet HIV"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101585_bib0070","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J cancer"},{"key":"10.1016\/j.eclinm.2022.101585_bib0071","series-title":"International Papillomavirus Conference","article-title":"Design of HPV vaccination trial among women living with HIV: Insights from meta-analytic review and modelling","author":"R\u00f6nn","year":"2015"},{"issue":"33","key":"10.1016\/j.eclinm.2022.101585_bib0072","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1016\/j.vaccine.2020.12.020","article-title":"Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9\u201314 in Kenya, Africa","volume":"39","author":"Mugo","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.eclinm.2022.101585_bib0073","unstructured":"ClinicalTrials.gov. Safety and Immunogenicity of GlaxoSmithKline Biologicals\u2019 HPV Vaccine 580299 (Cervarix) in HIV Infected Females. [cited 2021 Jan 3]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00586339"},{"issue":"48","key":"10.1016\/j.eclinm.2022.101585_bib0074","doi-asserted-by":"crossref","first-page":"5745","DOI":"10.1016\/j.vaccine.2013.09.032","article-title":"Safety and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled study","volume":"31","author":"Denny","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.eclinm.2022.101585_bib0075","unstructured":"ClinicalTrials.gov. Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection. [cited 2021 Jan 6]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00513526"},{"key":"10.1016\/j.eclinm.2022.101585_bib0076","doi-asserted-by":"crossref","unstructured":"ISRCTN registry. ISRCTN33674451: Human papillomavirus (HPV) vaccine in human immunodeficiency virus (HIV) positive girls and women. [cited 2021 Feb 1]. Available from: https:\/\/doi.org\/10.1186\/ISRCTN33674451.","DOI":"10.1186\/ISRCTN33674451"},{"issue":"15","key":"10.1016\/j.eclinm.2022.101585_bib0077","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1016\/j.vaccine.2020.02.075","article-title":"Impact of quadrivalent HPV vaccine dose spacing on immunologic response in women living with HIV","volume":"38","author":"McClymont","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.eclinm.2022.101585_bib0078","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pvr.2018.05.001","article-title":"A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men","volume":"6","author":"Ellsworth","year":"2018","journal-title":"Papillomavirus Res"},{"issue":"18","key":"10.1016\/j.eclinm.2022.101585_bib0079","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/j.vaccine.2019.03.034","article-title":"Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men","volume":"37","author":"Pinto","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.eclinm.2022.101585_bib0080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pvr.2016.01.001","article-title":"High specific immune response to a bivalent anti-HPV vaccine in HIV-1-infected men in S\u00e3o Paulo","volume":"2","author":"Fontes","year":"2016","journal-title":"Brazil. Papillomavirus Res."},{"key":"10.1016\/j.eclinm.2022.101585_bib0081","unstructured":"ClinicalTrials.gov. Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children. [cited 2021 Jan 20]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00339040"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101585_bib0082","first-page":"651","article-title":"[Evaluation of antibody response to HPV vaccination in HIV infected girls]","volume":"66","author":"O\u0142dakowska","year":"2012","journal-title":"Przegla\u0327d Epidemiol"},{"issue":"13","key":"10.1016\/j.eclinm.2022.101585_bib0083","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.vaccine.2016.02.019","article-title":"Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines","volume":"34","author":"Faust","year":"2016","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.eclinm.2022.101585_bib0084","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.4161\/hv.27925","article-title":"Comparison of the immunogenicity of Cervarix\u00ae and Gardasil\u00ae human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults","volume":"10","author":"Toft","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101585_bib0085","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12981-017-0160-0","article-title":"Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM)","volume":"14","author":"Hidalgo-Tenorio","year":"2017","journal-title":"AIDS Res Ther"},{"issue":"43","key":"10.1016\/j.eclinm.2022.101585_bib0086","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1016\/j.vaccine.2014.08.011","article-title":"Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults","volume":"32","author":"Giacomet","year":"2014","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101585_bib0087","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/21645515.2017.1407896","article-title":"Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection","volume":"14","author":"Zurek Munk-Madsen","year":"2018","journal-title":"Hum Vaccines Immunother."},{"issue":"3","key":"10.1016\/j.eclinm.2022.101585_bib0088","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1093\/cid\/ciaa1897","article-title":"Immunogenicity and Safety of the 9-Valent Human Papillomavirus Vaccine in Solid Organ Transplant Recipients and Adults Infected With Human Immunodeficiency Virus (HIV)","volume":"73","author":"Boey","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eclinm.2022.101585_bib0089","unstructured":"ClinicalTrials.gov. Study of Safety, Tolerability and Immunogenicity of Gardasil\u00ae9 in Immunocompromised Patients. [cited 2021 Jan 3]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03525210"},{"key":"10.1016\/j.eclinm.2022.101585_bib0090","unstructured":"ClinicalTrials.gov. Vaccine Therapy in Preventing HPV in HIV-Positive Women in India. clinicaltrials.gov. [cited 2021 Jan 3]. Available from: http:\/\/clinicaltrials.gov\/show\/NCT00667563"},{"key":"10.1016\/j.eclinm.2022.101585_bib0091","unstructured":"ClinicalTrials.gov. Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women. [cited 2021 Jan 3]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00604175"},{"key":"10.1016\/j.eclinm.2022.101585_bib0092","unstructured":"ClinicalTrials.gov. Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females. [cited 2022 Jan 19]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01031069"},{"key":"10.1016\/j.eclinm.2022.101585_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100353","article-title":"Immunogenicity and safety of the AS04-HPV-16\/18 and HPV-6\/11\/16\/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15\u201325 years: A phase IV randomized comparative study","volume":"23","author":"Folschweiller","year":"2020","journal-title":"EClinicalMedicine"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022003157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022003157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:13:13Z","timestamp":1762888393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537022003157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":93,"alternative-id":["S2589537022003157"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101585","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101585","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 World Health Organization. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101585"}}